A systematic review and meta-analysis by researchers at the University of Surrey, published in Nutrition Reviews, found that taking vitamin D2 supplements may reduce vitamin D3 levels in the body. This finding may call into question the assumption that vitamin D2 and D3 forms are complete, identical substitutes for one another in the body.
The study is particularly notable given the clear global upward trend in demand for vitamin D supplements. According to a 2026 report by the international research firm Mordor Intelligence, the global vitamin D therapy market was valued at USD 2.57 billion in 2025, is estimated at USD 2.85 billion for 2026, and is projected to reach USD 4.79 billion by 2031 (a compound annual growth rate of 10.94%). The fastest-growing segment is older adults (14.2% annual growth), driven by population aging, the prevalence of osteoporosis and osteopenia, and growing interest in preventive use.
Evaluating the new study’s findings and explaining in detail the specifics of taking vitamins D2 and D3 as well as modern medical approaches is Natia Romashvili, endocrinologist, nutritionist, and founder and president of the Georgian Society of Metabolic and Nutritional Medicine.
Based on your clinical practice, to what extent is demand for vitamin D supplements rising in Georgia, and what is the main motivation behind patients taking them?
Although there is no representative statistical data reflecting the dynamics of vitamin D consumption in Georgia, patient visits and interest in everyday clinical practice have increased noticeably. In our context, the main reason people take the supplement is often to prevent general weakness, fatigue, decreased immunity, or bone health issues, supported by wide access to information and the experience of the post-pandemic period.
However, it is important to keep in mind that heightened interest does not always mean supplementation is medically necessary. According to the Endocrine Society’s 2024 clinical guideline, while many associations have been observed between low blood 25(OH)D levels and various diseases, it has not been proven in every case that supplemental vitamin D reduces the risk of developing those conditions.
A systematic review and meta-analysis by researchers at the University of Surrey showed that taking vitamin D2 supplements may lower vitamin D3 levels in the body. Biochemically and endocrinologically, how is this interaction explained, and why does one form suppress the other?
Biochemically, D2 (ergocalciferol) and D3 (cholecalciferol) go through similar metabolic stages in the body: in the liver, D2 is converted into 25(OH)D2 and D3 into 25(OH)D3, after which their activation takes place mainly in the kidneys. The exact mechanism behind the drop in 25(OH)D3 when taking D2 has not been definitively established. One proposed explanation is increased breakdown (catabolism) of vitamin D metabolites, including through activation of the CYP24A1 enzyme. Scientifically, however, it is more accurate to say that D2 intake is associated with lower 25(OH)D3 levels than to claim that it directly suppresses D3 synthesis.
As for risks: a decrease in 25(OH)D3 does not mean that total vitamin D stores in the body are falling, because 25(OH)D2 concentrations rise at the same time. Furthermore, that meta-analysis evaluated only biochemical markers rather than clinical outcomes (such as fractures, infections, or mortality). Accordingly, there is currently no evidence that this biochemical shift by itself increases the risk of any complication.
It has often been assumed that vitamins D2 and D3 act identically in the body and serve as full replacements for one another. Given these study findings, how effective is vitamin D2 really for improving overall status if it simultaneously reduces existing D3 stores?
Both forms increase total 25(OH)D concentration in the blood and participate in regulating calcium and phosphorus metabolism, though their effectiveness is not completely identical.
A 2024 meta-analysis showed that taking vitamin D2 increased total 25(OH)D concentration by an average of 11.47 ng/mL—even though 25(OH)D3 levels dropped by an average of 4.63 ng/mL, that decline was fully offset by the rise in 25(OH)D2 (+11.40 ng/mL). The biological activity of D2 is also supported by a 26-study meta-analysis published in Nutrition Reviews in 2026, which found that D2 lowered parathyroid hormone levels and supported calcium balance.
Thus, vitamin D2 is genuinely effective for improving vitamin D status, though comparative studies and data from the U.S. National Institutes of Health (NIH) confirm that D3 raises total 25(OH)D more effectively and maintains the achieved level longer.
The study authors emphasize that for immune support and raising overall status, it is better to choose vitamin D3 (including plant-based D3 derived from lichen). Among the products available in pharmacies in Georgia, which form is preferred, and what should patients pay attention to on the packaging?
When the goal is a rapid and steady improvement in blood vitamin D status, vitamin D3 (cholecalciferol) is preferred in terms of biochemical efficacy.
The vast majority of products available in pharmacies in Georgia also come in the D3 form (as drops, capsules, or tablets). Regarding the immune system, a 2022 study published in Frontiers in Immunology found that D3 intake activated genes linked to the type I interferon signaling pathway (important for early antiviral response), whereas no similar effect was seen with D2. However, that study assessed gene expression rather than clinical infection rates, so the clinical superiority of D3 for immune protection is not yet definitively proven.
When buying a supplement, a patient should pay attention to three key details on the label:
-
Active ingredient: Cholecalciferol (vitamin D3) or Ergocalciferol (vitamin D2);
-
Dosage: Listed in international units (IU) or micrograms (mcg)—1 mcg equals 40 IU;
-
Source of origin (when relevant): Traditional D3 is obtained from sheep’s wool lanolin, while for a vegan alternative, the packaging should indicate a plant source—lichen (Lichen).
Are there specific clinical situations or patient groups (such as vegans or people with certain medical indications) who have traditionally been prescribed vitamin D2, and should that approach change in light of new scientific data? What approach do you follow in your clinical practice?
Historically, D2 (derived from mushrooms and yeast) was the main alternative for vegans and people who do not consume animal-derived products. Today, plant-based D3 derived from lichen is available, allowing vegans to take the D3 form—which has higher bioavailability—without compromising their dietary principles.
Even so, the findings of the 2025 meta-analysis do not provide grounds to declare D2 ineffective or replace it entirely. In my clinical practice, I generally prefer D3, though the choice is always individualized.
A tailored approach is needed for patients with malabsorption (impaired fat absorption), celiac disease, inflammatory bowel disease, or after bariatric surgery. According to the 2024 international consensus in Endocrine Reviews, absorption differences in such patients may require a different dosing regimen or consideration of calcifediol (the preformed 25(OH)D3 form). Likewise, in chronic kidney disease, treatment strategy depends on specific mechanisms of calcium-phosphorus metabolism.
Along with the global rise in vitamin D use, self-medication without a doctor’s prescription or prior laboratory testing has become more common. What risks are associated with self-medicating using an improperly chosen form or dose?
Vitamin D is a fat-soluble vitamin that accumulates in the body, and excessive intake can cause toxic effects. The primary mechanism of toxicity is excessive calcium absorption from the gut and hypercalcemia. This condition manifests with nausea, vomiting, constipation, loss of appetite, severe thirst, frequent urination, and weakness, while severe cases can lead to kidney damage (nephrocalcinosis), soft-tissue calcification, and heart rhythm disturbances.
A meta-analysis published in 2023 showed that long-term intake of 3,200–4,000 IU of vitamin D per day increased the risk of hypercalcemia 2.21-fold compared with the control group. The tolerable upper intake level set for adults by the U.S. National Academies is 4,000 IU per day. Higher doses are used only to treat confirmed deficiency, under medical supervision and for a defined period.
The main danger of self-medication is precisely the prolonged, uncontrolled intake of unnecessarily high doses and overlooking the cumulative dose obtained from multiple combination products.
When a patient gets a blood test to measure vitamin D, does a standard test provide information on D2 and D3 concentrations separately, or do we see only a total figure—and how important is knowing this difference for planning proper treatment?
To assess blood vitamin D status, total 25-hydroxyvitamin D—25(OH)D—is measured, combining both metabolites: 25(OH)D2 and 25(OH)D3. In routine clinical practice, measuring this total level is primary and quite sufficient.
Accurate, separate measurement of individual fractions—25(OH)D2 and 25(OH)D3—is possible using a specialized method such as LC-MS/MS (liquid chromatography-tandem mass spectrometry). This is especially informative for patients taking D2, because some standard immunoassay test systems have low sensitivity for 25(OH)D2, and the total value may not fully reflect response to therapy.
It is also essential to remember that testing the active metabolite—1,25(OH)₂D (calcitriol)—is not used to assess vitamin D stores. Its level in the body is tightly regulated by calcium-phosphorus metabolism and parathyroid hormone mechanisms, so it often remains within the normal range even during deficiency and does not reflect true body stores.
Could increased vitamin D consumption reveal additional side effects in the long term?
In the long term, the main risk is linked to prolonged use of high doses, which can cause hypercalcemia, hypercalciuria (excess calcium excretion in urine), kidney stone disease, and calcification of blood vessels or soft tissues. In addition, a 2023 meta-analysis also noted an increased risk of falls and hospitalization in certain groups under prolonged high dosing.
That is why the Endocrine Society’s 2024 guideline favors daily, relatively lower doses rather than intermittent (for example, monthly) ultra-high bolus doses for people aged 50 and older. As for the decrease in 25(OH)D3 when taking D2, the long-term clinical impact of this biochemical phenomenon requires further study and is not currently considered a toxic effect.

